What is the most common gene for lung cancer?

Several genes are associated with lung cancer, but the most common genetic alterations in lung cancer often involve mutations in genes related to cell growth and division. Two of the most prevalent genetic mutations in non-small cell lung cancer (NSCLC), which is the most common type of lung cancer, are mutations in the EGFR (epidermal growth factor receptor) gene and mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog) gene.

1. **EGFR (Epidermal Growth Factor Receptor):**
- EGFR is a gene that codes for a protein involved in cell growth and division. Mutations in the EGFR gene can lead to the continuous activation of the EGFR protein, promoting uncontrolled cell growth. EGFR mutations are more common in certain subtypes of lung cancer, such as adenocarcinoma, and are more frequently found in non-smokers or light smokers.

2. **KRAS (Kirsten rat sarcoma viral oncogene homolog):**
- KRAS is another gene associated with cell growth and division. Mutations in KRAS can result in the constant activation of the KRAS protein, contributing to the development and progression of cancer. KRAS mutations are often found in adenocarcinomas of the lung and are more common in smokers.

It's important to note that these mutations are not the only ones associated with lung cancer, and other genetic alterations, such as mutations in the TP53 tumor suppressor gene, ALK (anaplastic lymphoma kinase) rearrangements, and ROS1 rearrangements, also play significant roles in lung cancer development.

The prevalence of specific genetic mutations can vary among different populations and subtypes of lung cancer. Additionally, advancements in genomic research continue to uncover new genetic markers and potential targets for therapy in lung cancer. As our understanding of the molecular basis of lung cancer expands, targeted therapies are being developed to specifically address the genetic abnormalities driving the growth of cancer cells. It's essential for healthcare professionals to perform comprehensive genetic testing to identify specific mutations in individual patients, as this information can guide treatment decisions and improve outcomes.